Alex Yang
Fortuna: 46 M $ al 31/08/2026
Fortuna: 46 M $ al 31/08/2026
Alex Yang is currently Chairman & Chief Executive Officer at Polaryx Therapeutics, Inc. since 2023, Chairman & Chief Executive Officer at Epygenix Therapeutics, Inc., and Chief Executive Officer at Mstone Partners Hong Kong Ltd. Formerly, Mr. Yang was Managing Partner at Kim & Chang.
Education includes undergraduate studies at State University of New York at Binghamton and graduate studies at New York University School of Law.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
POLARYX THERAPEUTICS, INC. 45,81 % | 27/07/2026 | 22.833.249 ( 45,81 % ) | 46 M $ | 31/08/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| POLARYX THERAPEUTICS, INC. | Director Ejecutivo | 01/03/2023 |
Epygenix Therapeutics, Inc.
Epygenix Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutics for neurological disorders | Director Ejecutivo | - |
Mstone Partners Hong Kong Ltd. | Director Ejecutivo | - |
| Empresas | Cargo | Fin |
|---|---|---|
Kim & Chang
Kim & Chang Miscellaneous Commercial ServicesCommercial Services Provides legal services | Corporate Officer/Principal | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 6 |
|---|---|
Kim & Chang
Kim & Chang Miscellaneous Commercial ServicesCommercial Services Provides legal services | Commercial Services |
State University of New York at Binghamton
State University of New York at Binghamton Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
New York University School of Law
New York University School of Law Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Mstone Partners Hong Kong Ltd. | |
Epygenix Therapeutics, Inc.
Epygenix Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutics for neurological disorders | Health Technology |
Polaryx Therapeutics, Inc.
Polaryx Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a clinical-stage biotechnology company that engages in discovery, development and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders | Commercial Services |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.